Fifth Third Wealth Advisors LLC Takes $241,000 Position in Masimo Co. (NASDAQ:MASI)

Fifth Third Wealth Advisors LLC bought a new position in shares of Masimo Co. (NASDAQ:MASI - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 1,456 shares of the medical equipment provider's stock, valued at approximately $241,000.

A number of other institutional investors have also recently made changes to their positions in the business. NBC Securities Inc. lifted its holdings in Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider's stock worth $30,000 after buying an additional 73 shares during the last quarter. MML Investors Services LLC increased its stake in Masimo by 4.9% in the third quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider's stock valued at $274,000 after purchasing an additional 96 shares during the last quarter. Assetmark Inc. raised its holdings in Masimo by 12.7% during the third quarter. Assetmark Inc. now owns 1,183 shares of the medical equipment provider's stock worth $158,000 after purchasing an additional 133 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Masimo by 0.7% during the 4th quarter. Nordea Investment Management AB now owns 19,182 shares of the medical equipment provider's stock worth $3,206,000 after buying an additional 142 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Masimo by 3.2% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 5,374 shares of the medical equipment provider's stock valued at $677,000 after buying an additional 166 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Masimo Trading Up 1.4 %

Shares of Masimo stock traded up $2.35 during trading hours on Friday, reaching $172.29. 616,441 shares of the company's stock were exchanged, compared to its average volume of 413,973. The firm has a market capitalization of $9.22 billion, a price-to-earnings ratio of 118.82 and a beta of 1.01. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $180.97. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The company has a fifty day moving average of $169.23 and a 200-day moving average of $140.13.

Masimo (NASDAQ:MASI - Get Free Report) last issued its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $504.60 million for the quarter, compared to the consensus estimate of $502.87 million. During the same quarter last year, the firm posted $0.63 EPS. The business's revenue for the quarter was up 5.4% compared to the same quarter last year. Sell-side analysts forecast that Masimo Co. will post 4.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on MASI. Piper Sandler raised their target price on shares of Masimo from $180.00 to $210.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 18th. BTIG Research lifted their price objective on shares of Masimo from $166.00 to $170.00 and gave the company a "buy" rating in a research note on Monday, October 14th. Stifel Nicolaus reissued a "buy" rating and set a $190.00 price target (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Raymond James upped their price objective on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research note on Friday, December 27th. Finally, Wells Fargo & Company raised their target price on shares of Masimo from $171.00 to $193.00 and gave the company an "overweight" rating in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $179.67.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.